Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Depriving women of this drug is good public health

Patricia Bencivenga and Adriane Fugh-Berman, MD
Meds
November 19, 2022
1 Shares
Share
Tweet
Share

It’s a public health win that on October 19th, an FDA Advisory Committee voted 14-1 to remove Makena, a drug intended to prevent preterm birth, from the market. The FDA usually follows the advice of its advisory committee, and the briefing documents it supplied the committee make it clear that the agency wants the drug off the market. As well it should. Makena doesn’t work.

After a preliminary trial showed that women assigned to Makena had fewer preterm births than women assigned to placebo, the FDA granted “accelerated approval” to the drug – a temporary, conditional approval designed to speed promising therapies to the public while definitive studies on patient benefits are being done. In this case, the larger, carefully designed follow-up study was designed to see if babies were born healthier, not just later. The study found no benefits to babies, and Makena also showed no benefit over placebo in preventing preterm birth.

That should have been the end of the story — but no. Even after an FDA advisory committee voted 9 to 7 to remove the drug in 2019, the manufacturer fought back, necessitating an unusual second advisory committee meeting.

Public comments at the recent meeting supporting the drug struck three common themes: Preterm birth is a large problem, especially among Black women; Makena is the only FDA-approved therapy, and keeping Makena on the market is important to avoid racial inequities in health care.

It’s certainly true that Black women are at higher risk for preterm birth. Makena won’t help, though; the drug didn’t work in the full population or any sub-group, including Black women. It’s true – but a bit misleading – to say that Makena is the only approved therapy on the market. It was approved conditionally, with the understanding that it could be withdrawn if a confirmatory trial didn’t show benefit.

What is patently not true is that removing Makena from the market disadvantages Black women. Stopping access to a drug that doesn’t work is good public health and exactly what the FDA is supposed to do.

The similarities in the arguments of the groups that testified to keep Makena available were not coincidental. The National Consumers League, Healthy Women, Sidelines, and Miracle Babies, and Dr. Hugh Miller of the WOMB foundation (apparently a contract research organization) all accepted support from at least one of Makena’s manufacturers. The Preterm Birth Prevention Alliance, a project of the National Consumers League, was started by Covis, Makena’s current manufacturer. All of these groups, unsurprisingly, testified to keep Makena on the market.

All representatives from these industry-funded groups ignored the overwhelming evidence that Makena doesn’t work to prevent preterm birth. Every day that the drug is on the market means more profits for Covis. Makena costs more than $700 per weekly injection; Medicaid spends hundreds of millions of dollars a year on the drug – a truly stunning sum to pay for a repackaged drug; the original version has been around for 70 years.

Taxpayers have been on the hook for an expensive drug that doesn’t work since Makena was approved in 2011. Enough is enough. Consumer groups that support ineffective, expensive drugs represent the interests of corporations, not patients. If these groups cared about women and babies, they would support effective prevention measures rather than shilling for an ineffective and expensive drug. We need more comparative research on therapies supported by randomized controlled trials, including cervical cerclage (a surgical procedure), vaginal progesterone, and fish oil, and need more research on the effect of midwifery care and screening for lower genital tract infections.

Makena is a branded version of an old drug, and it doesn’t improve birth outcomes. The committee vote is a resounding and deserved rejection. No one needs a drug that doesn’t work.

Patricia Bencivenga is a special projects coordinator and Adriane Fugh-Berman is a professor of pharmacology and physiology.

Image credit: Shutterstock.com

Prev

Political creep: government intrusion in health care

November 19, 2022 Kevin 10
…
Next

We’re confusing resilience with grit [PODCAST]

November 19, 2022 Kevin 0
…

Tagged as: OB/GYN

Post navigation

< Previous Post
Political creep: government intrusion in health care
Next Post >
We’re confusing resilience with grit [PODCAST]

Related Posts

  • Low income is a neglected public health issue

    Vania Silva
  • Why working at polling locations is good public health

    Rob Palmer, Isaac Freedman, and Josh Hyman
  • Our public health efforts depend on flexibility and trust

    John Connolly
  • The public health solution to gun deaths

    Nancy Dodson, MD, MPH, Jeffrey Oestreicher, MD and Nina Agrawal, MD
  • Are negative news cycles and social media injurious to our health?

    Rabia Jalal, MD
  • The public health emergency brought health care into the 21st century. Let’s keep moving forward.

    Stephen Parodi, MD

More in Meds

  • The real cause of America’s opioid crisis: Doctors are not to blame

    Richard A. Lawhern, PhD
  • Can personalized medicine live up to its hype in health care?

    Ketan Desai, MD, PhD
  • The effects of the nationwide stimulant shortage on a private psychiatry practice

    Christine Tran-Boynes, DO
  • Why North American medical cannabis can’t compete globally

    Michael Sassano
  • How were we duped and what can we do about the opioid overdose crisis?

    Ronald A. Zent, MD
  • Caught in the middle: How health insurance companies influence cancer drug selection

    Paul Pender, MD
  • Most Popular

  • Past Week

    • Nobody wants this job. Should physicians stick around?

      Katie Klingberg, MD | Physician
    • Healing the damaged nurse-physician dynamic

      Angel J. Mena, MD and Ali Morin, MSN, RN | Policy
    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • From physician to patient: one doctor’s journey to finding purpose after a devastating injury

      Stephanie Pearson, MD | Physician
    • Breaking the stigma: Addressing the struggles of physicians

      Jean Antonucci, MD | Physician
    • Breaking the cycle of misery in medicine: a practical guide

      Paul R. Ehrmann, DO | Physician
  • Past 6 Months

    • The hidden dangers of the Nebraska Heartbeat Act

      Meghan Sheehan, MD | Policy
    • The fight for reproductive health: Why medication abortion matters

      Catherine Hennessey, MD | Physician
    • The vital importance of climate change education in medical schools

      Helen Kim, MD | Policy
    • Resetting the doctor-patient relationship: Navigating the challenges of modern primary care

      Jeffrey H. Millstein, MD | Physician
    • Nobody wants this job. Should physicians stick around?

      Katie Klingberg, MD | Physician
    • Why are doctors sued and politicians aren’t?

      Kellie Lease Stecher, MD | Physician
  • Recent Posts

    • Unlock the power of physician compensation data in contract negotiations [PODCAST]

      The Podcast by KevinMD | Podcast
    • From pennies to attending salaries: Why physicians should teach their kids financial literacy

      Michele Cho-Dorado, MD | Finance
    • From solidarity to co-liberation: Understanding the journey towards ending oppression

      Maiysha Clairborne, MD | Physician
    • Changing the pediatric care landscape: Integrating behavioral and mental health care

      Hilary M. Bowers, MD | Conditions
    • Contract Diagnostics is the only firm 100 percent dedicated to physician contract reviews

      Contract Diagnostics | Sponsored
    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

Leave a Comment

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • Pregnant, Black? Here's Your Drug Test
  • Progestin-Only Birth Control Linked to Small Increase in Breast Cancer Risk
  • Fatty Acid Tube Feeding May Backfire for Preemie Breathing Disorder
  • Case Reports Detail Vision Loss Linked to Recalled Artificial Tears
  • Admin Trumps Med Students: Anti-Abortion Group Allowed on Campus

Meeting Coverage

  • Outlook for Itchy Prurigo Nodularis Continues to Improve With IL-31 Antagonist
  • AAAAI President Shares Highlights From the 2023 Meeting
  • Second-Line Sacituzumab Govitecan Promising in Platinum-Ineligible UC
  • Trial of Novel TYK2 Inhibitor Hits Its Endpoint in Plaque Psoriasis
  • Durable Vitiligo Responses With Topical Ruxolitinib
  • Most Popular

  • Past Week

    • Nobody wants this job. Should physicians stick around?

      Katie Klingberg, MD | Physician
    • Healing the damaged nurse-physician dynamic

      Angel J. Mena, MD and Ali Morin, MSN, RN | Policy
    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • From physician to patient: one doctor’s journey to finding purpose after a devastating injury

      Stephanie Pearson, MD | Physician
    • Breaking the stigma: Addressing the struggles of physicians

      Jean Antonucci, MD | Physician
    • Breaking the cycle of misery in medicine: a practical guide

      Paul R. Ehrmann, DO | Physician
  • Past 6 Months

    • The hidden dangers of the Nebraska Heartbeat Act

      Meghan Sheehan, MD | Policy
    • The fight for reproductive health: Why medication abortion matters

      Catherine Hennessey, MD | Physician
    • The vital importance of climate change education in medical schools

      Helen Kim, MD | Policy
    • Resetting the doctor-patient relationship: Navigating the challenges of modern primary care

      Jeffrey H. Millstein, MD | Physician
    • Nobody wants this job. Should physicians stick around?

      Katie Klingberg, MD | Physician
    • Why are doctors sued and politicians aren’t?

      Kellie Lease Stecher, MD | Physician
  • Recent Posts

    • Unlock the power of physician compensation data in contract negotiations [PODCAST]

      The Podcast by KevinMD | Podcast
    • From pennies to attending salaries: Why physicians should teach their kids financial literacy

      Michele Cho-Dorado, MD | Finance
    • From solidarity to co-liberation: Understanding the journey towards ending oppression

      Maiysha Clairborne, MD | Physician
    • Changing the pediatric care landscape: Integrating behavioral and mental health care

      Hilary M. Bowers, MD | Conditions
    • Contract Diagnostics is the only firm 100 percent dedicated to physician contract reviews

      Contract Diagnostics | Sponsored
    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds

MedPage Today Professional

An Everyday Health Property Medpage Today iMedicalApps
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Leave a Comment

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...